Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL-1β and the inflammasome pathway.

IF 20.1 1区 医学 Q1 ONCOLOGY
Xuejiao Han, Yuan Cheng, Dandan Wan, Aqu Alu, Ziqi Zhang, Zhenfei Bi, Manni Wang, Yan Tang, Weiqi Hong, Siyuan Chen, Li Chen, Yuquan Wei
{"title":"Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL-1β and the inflammasome pathway.","authors":"Xuejiao Han, Yuan Cheng, Dandan Wan, Aqu Alu, Ziqi Zhang, Zhenfei Bi, Manni Wang, Yan Tang, Weiqi Hong, Siyuan Chen, Li Chen, Yuquan Wei","doi":"10.1002/cac2.70024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is a key treatment modality in cancer therapy, utilizing high-energy radiation to directly kill tumor cells. Recent research has increasingly highlighted RT's potential to indirectly enhance antitumor immunity. However, this immune activation alone often fails to generate sustained systemic antitumor responses. In this study, we aimed to investigate the antitumor effects of combining cholesterolized toll-like receptor 7 (TLR7) agonist liposomes, specifically 1V209-Cho-Lip, with RT.</p><p><strong>Methods: </strong>Mouse tumor models were used to assess the impact of combining 1V209-Cho-Lip with RT on tumor progression and modification of the tumor microenvironment. In vitro, primary mouse bone marrow-derived dendritic cells (BMDCs) were utilized to investigate changes in function and the activated pathways through RNA sequencing. Additionally, we explored the role of oxidized mitochondrial DNA (ox-mtDNA) released from irradiated tumor cells as a damage-associated molecular pattern in modulating immune responses. The involvement of interleukin-1β (IL-1β) and the inflammasome pathway in the antitumor efficacy of the combined treatment was evaluated using Il-1β<sup>-/-</sup> and cysteinyl aspartate specific proteinase 1 knockout (Casp1<sup>-/-</sup>) mouse models.</p><p><strong>Results: </strong>The combination of 1V209-Cho-Lip and RT significantly inhibited tumor growth and induced antitumor immunity in tumor models. This combination therapy enhanced maturation, antigen presentation and IL-1β secretion of dendritic cells (DCs) in vitro. Ox-mtDNA released from irradiated tumor cells synergized with 1V209-Cho-Lip to activate the inflammasome pathway in DCs. The antitumor effect of the combined therapy was significantly reduced in Il-1β<sup>-/-</sup> and Casp1<sup>-/-</sup> mice.</p><p><strong>Conclusions: </strong>This study suggests that the combination of 1V209-Cho-Lip with RT might be a promising antitumor strategy and further studies are warranted to explore the clinical relevance of this combination therapy.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":" ","pages":""},"PeriodicalIF":20.1000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cac2.70024","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Radiotherapy (RT) is a key treatment modality in cancer therapy, utilizing high-energy radiation to directly kill tumor cells. Recent research has increasingly highlighted RT's potential to indirectly enhance antitumor immunity. However, this immune activation alone often fails to generate sustained systemic antitumor responses. In this study, we aimed to investigate the antitumor effects of combining cholesterolized toll-like receptor 7 (TLR7) agonist liposomes, specifically 1V209-Cho-Lip, with RT.

Methods: Mouse tumor models were used to assess the impact of combining 1V209-Cho-Lip with RT on tumor progression and modification of the tumor microenvironment. In vitro, primary mouse bone marrow-derived dendritic cells (BMDCs) were utilized to investigate changes in function and the activated pathways through RNA sequencing. Additionally, we explored the role of oxidized mitochondrial DNA (ox-mtDNA) released from irradiated tumor cells as a damage-associated molecular pattern in modulating immune responses. The involvement of interleukin-1β (IL-1β) and the inflammasome pathway in the antitumor efficacy of the combined treatment was evaluated using Il-1β-/- and cysteinyl aspartate specific proteinase 1 knockout (Casp1-/-) mouse models.

Results: The combination of 1V209-Cho-Lip and RT significantly inhibited tumor growth and induced antitumor immunity in tumor models. This combination therapy enhanced maturation, antigen presentation and IL-1β secretion of dendritic cells (DCs) in vitro. Ox-mtDNA released from irradiated tumor cells synergized with 1V209-Cho-Lip to activate the inflammasome pathway in DCs. The antitumor effect of the combined therapy was significantly reduced in Il-1β-/- and Casp1-/- mice.

Conclusions: This study suggests that the combination of 1V209-Cho-Lip with RT might be a promising antitumor strategy and further studies are warranted to explore the clinical relevance of this combination therapy.

通过胆固醇化TLR7激动剂脂质体和放疗联合增强抗肿瘤免疫:IL-1β和炎性体途径的作用
背景:放射治疗(RT)是肿瘤治疗的一种关键治疗方式,利用高能辐射直接杀伤肿瘤细胞。最近的研究越来越强调RT间接增强抗肿瘤免疫的潜力。然而,这种单独的免疫激活往往不能产生持续的全身抗肿瘤反应。在本研究中,我们旨在探讨胆固醇化toll样受体7 (TLR7)激动剂脂质体,特别是1V209-Cho-Lip与RT联合使用的抗肿瘤作用。方法:采用小鼠肿瘤模型,评估1V209-Cho-Lip与RT联合使用对肿瘤进展和肿瘤微环境改变的影响。体外,利用原代小鼠骨髓源性树突状细胞(bmdc),通过RNA测序研究其功能变化和激活途径。此外,我们探索了从辐照肿瘤细胞释放的氧化线粒体DNA (ox-mtDNA)在调节免疫反应中的损伤相关分子模式的作用。采用IL-1β -/-和半胱氨酸天冬氨酸特异性蛋白酶1敲除(Casp1-/-)小鼠模型,评估白介素-1β (IL-1β)和炎性体途径在联合治疗抗肿瘤疗效中的作用。结果:1V209-Cho-Lip联合RT可显著抑制肿瘤生长,诱导抗肿瘤免疫。这种联合治疗增强了体外树突状细胞(dc)的成熟、抗原呈递和IL-1β分泌。辐照肿瘤细胞释放的Ox-mtDNA与1V209-Cho-Lip协同激活dc中炎性体通路联合治疗对Il-1β-/-和Casp1-/-小鼠的抗肿瘤作用显著降低。结论:本研究提示1V209-Cho-Lip联合RT可能是一种很有前景的抗肿瘤策略,需要进一步的研究来探索这种联合治疗的临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信